STERIS (STE) Projected to Announce Quarterly Earnings on Wednesday

STERIS (NYSE:STE) is anticipated to issue its Q2 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $2.67 per share and revenue of $1.56 billion for the quarter. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Individuals may review the information on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. The firm had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $2.34 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, analysts expect STERIS to post $11.17 EPS for the current fiscal year and $12.40 EPS for the next fiscal year.

STERIS Trading Down 0.6%

Shares of STERIS stock opened at $227.06 on Wednesday. STERIS has a 12 month low of $195.14 and a 12 month high of $269.44. The stock has a 50 day moving average of $220.16 and a 200 day moving average of $225.65. The firm has a market cap of $22.14 billion, a PE ratio of 27.89 and a beta of 0.92.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 25th. Investors of record on Friday, September 4th were paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a yield of 1.2%. This is a positive change from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend was Friday, September 4th. STERIS’s payout ratio is presently 33.74%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. UBS Group cut their price objective on shares of STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings restated a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus price target of $271.33.

Insiders Place Their Bets

In other STERIS news, Director Mohsen Sohi sold 4,058 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total value of $956,795.24. Following the sale, the director owned 24,305 shares of the company’s stock, valued at approximately $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.12% of the stock is owned by corporate insiders.

STERIS Company Profile

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.